| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer (NCT04418219) | Thomas Jefferson University | 2020-12-21 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer (NCT04052555) | National Cancer Institute (NCI) | 2020-09-24 |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (NCT03939897) | National Cancer Institute (NCI) | 2020-06-17 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (NCT03554044) | University of California, San Francisco | 2020-02-05 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer (NCT03737695) | Mayo Clinic | 2019-09-16 |
| Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer (NCT03941730) | Mayo Clinic | 2019-08-28 |
| Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer (NCT04022772) | M.D. Anderson Cancer Center | 2019-07-31 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (NCT03971409) | Laura Huppert, MD, BA | 2019-07-08 |
| Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer (NCT03207529) | M.D. Anderson Cancer Center | 2019-06-07 |
| Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences (NCT03955640) | Thomas Jefferson University | 2019-05-20 |
| Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer (NCT03644589) | University of Washington | 2019-04-01 |
| Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice (NCT04297384) | Roswell Park Cancer Institute | 2019-02-06 |
| ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors (NCT03725436) | M.D. Anderson Cancer Center | 2019-01-24 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (NCT03432741) | Mayo Clinic | 2018-03-27 |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity (NCT03418961) | SWOG Cancer Research Network | 2017-11-01 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer (NCT03364348) | George W. Sledge Jr. | 2017-10-30 |
| Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer (NCT03213041) | Northwestern University | 2017-09-14 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery (NCT03044730) | Northwestern University | 2017-05-25 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207) | National Cancer Institute (NCI) | 2017-05-19 |
| Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer (NCT02996825) | City of Hope Medical Center | 2017-03-22 |
| Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases (NCT02595905) | National Cancer Institute (NCI) | 2016-09-15 |
| Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis (NCT02774681) | Northwestern University | 2016-08-31 |
| Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery (NCT02658812) | M.D. Anderson Cancer Center | 2016-08-01 |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (NCT02824575) | Montefiore Medical Center | 2016-07-01 |
| Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer (NCT02672475) | Vanderbilt-Ingram Cancer Center | 2016-03-01 |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer (NCT02627430) | National Cancer Institute (NCI) | 2016-03-01 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors (NCT02650635) | Mayo Clinic | 2016-02-05 |
| MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer (NCT02536794) | Northwestern University | 2016-01-14 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319) | Mayo Clinic | 2016-01-01 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer (NCT02157051) | University of Washington | 2015-06-01 |
| Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (NCT02311933) | National Cancer Institute (NCI) | 2015-05-28 |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery (NCT02219789) | Mayo Clinic | 2014-12-05 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (NCT02208375) | M.D. Anderson Cancer Center | 2014-11-11 |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer (NCT02206334) | NRG Oncology | 2014-08-01 |
| Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (NCT02152943) | M.D. Anderson Cancer Center | 2014-07-17 |
| Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery (NCT01816035) | University of Washington | 2014-06-01 |
| Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (NCT02115282) | National Cancer Institute (NCI) | 2014-03-29 |
| Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (NCT01922921) | University of Washington | 2014-02-05 |
| Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer (NCT01908101) | University of Washington | 2014-01-08 |
| Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer (NCT02415387) | Ohio State University Comprehensive Cancer Center | 2014-01-01 |
| Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer (NCT01776008) | National Cancer Institute (NCI) | 2013-01-01 |
| Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer (NCT01622868) | National Cancer Institute (NCI) | 2012-12-06 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (NCT01552434) | M.D. Anderson Cancer Center | 2012-10-16 |
| Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer (NCT02370264) | University of Southern California | 2012-10-01 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01624441) | National Cancer Institute (NCI) | 2012-08-21 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer (NCT01463072) | City of Hope Medical Center | 2012-06-19 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer (NCT01575522) | National Cancer Institute (NCI) | 2012-03-01 |
| Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (NCT01434303) | National Cancer Institute (NCI) | 2012-01-10 |
| PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (NCT01697293) | Prescient Therapeutics, Ltd. | 2012-01-01 |
| Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer (NCT01349959) | National Cancer Institute (NCI) | 2011-08-15 |
| Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer (NCT01351909) | National Cancer Institute (NCI) | 2011-05-02 |
| MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer (NCT01344031) | National Cancer Institute (NCI) | 2011-04-21 |
| Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer (NCT01327781) | National Cancer Institute (NCI) | 2011-03-25 |
| Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer (NCT01277757) | National Cancer Institute (NCI) | 2011-03-01 |
| Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer (NCT01275677) | National Cancer Institute (NCI) | 2011-02-08 |
| MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer (NCT01263145) | National Cancer Institute (NCI) | 2011-01-05 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors (NCT01281150) | National Cancer Institute (NCI) | 2011-01-01 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery (NCT01276496) | National Cancer Institute (NCI) | 2010-12-01 |
| Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (NCT01251874) | National Cancer Institute (NCI) | 2010-11-22 |
| RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer (NCT01149356) | National Cancer Institute (NCI) | 2010-10-01 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer (NCT01217411) | National Cancer Institute (NCI) | 2010-10-01 |
| F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy (NCT02149173) | University of Washington | 2010-09-15 |
| Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (NCT01145430) | National Cancer Institute (NCI) | 2010-06-01 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (NCT01131234) | National Cancer Institute (NCI) | 2010-05-01 |
| Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer (NCT00998738) | Mayo Clinic | 2009-11-01 |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (NCT00699491) | National Cancer Institute (NCI) | 2008-10-31 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (NCT00785291) | National Cancer Institute (NCI) | 2008-10-13 |
| Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (NCT00601900) | National Cancer Institute (NCI) | 2008-09-24 |
| Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU (NCT00520975) | National Cancer Institute (NCI) | 2007-11-01 |
| Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery (NCT00450879) | National Cancer Institute (NCI) | 2007-01-01 |
| Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive (NCT00390455) | National Cancer Institute (NCI) | 2006-09-15 |
| Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer (NCT00376688) | National Cancer Institute (NCI) | 2006-07-11 |
| Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer (NCT00100750) | National Cancer Institute (NCI) | 2005-09-01 |
| Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen (NCT00118157) | National Cancer Institute (NCI) | 2005-05-01 |
| Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (NCT00066690) | ETOP IBCSG Partners Foundation | 2003-12-17 |
| Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer (NCT00054132) | National Cancer Institute (NCI) | 2002-12-01 |